ID   UKF-NB-3rDACARB8
AC   CVCL_RQ61
SY   UKF-NB-3rDAC8
DR   Wikidata; Q54990335
RX   PubMed=22170099;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; (5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide)).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9904 ! UKF-NB-3
SX   Female
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 8
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//